Pharma and biotech companies can't justify IPR opt outs, but you can see why they are asking for them
The pharmaceutical and biotechnology industries seem to be stepping up their attempts to secure a carve-out for biopharmaceutical patents from the IPR process. Last week, Jim Greenwood, the president and CEO of BIO and John Castellani, the president…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now